Last updated on September 2018

A Phase 3 clinical study for patients with follicular lymphoma


Brief description of study

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Clinical Study Identifier: NCT02213263

Contact Investigators or Research Sites near you

Start Over

Chonbuk National University Hospital
Jeonju-si, Korea, Republic of